Highlights

  • 13 Jun 2017
    - Highlights

    EBE Webinar: IP and its crucial role in bringing innovative medicines to patients

    20 June 2017 from 4H30 - 5H30 CET

    Europe has good science and sound Intellectual Property (IP) policies in place. These IP policies and other incentive offered by legislation when medicines are developed play a critical role in companies corporate and product development strategies.

    Read Barbara Freischem's pdf presentation here
    .
    The full recordng of the webinar is now availabe here.

    Read more |
  • 02 Jun 2017
    - Highlights

    Reinventing the European Advanced Therapies Sector: An Interview with Eduardo Bravo

    In this interview with Eduardo Bravo, CEO of TiGenix and President of the Board of the European Biopharmaceutical Enterprises (EBE), we discuss the increasing challenge for EU biotech companies to commercialise at home, and the accelerating departure of cutting-edge European biotech start-ups through IPOs and, increasingly, mergers and acquisitions.

    Interview by Duane Schulthess/Vitaltransformation.com

    Read more |
  • 30 May 2017
    - Highlights

    Final Call ATMP Survey: Help improve product development and regulation

    Response deadline: 30 June 2017 

    Advanced Therapy Medicinal Products (ATMPs) are medicinal products including gene therapies, somatic cell therapies and tissue engineered products. They are characterised by their innovative character. Despite considerable development activity in this dynamic field, a limited number of ATMPs have received Marketing Authorisation in the European Union. There is a growing urgency to understand which factors are associated with the advancement of ATMPs through the medicines life-cycle.

    Read more |
  • 09 May 2017
    - Highlights

    What pricing and reimbursement policies to use for off-patent biologicals? – Results from the second EBE biological medicines policy survey

    Objective: Biosimilar policies with a focus on uptake have received a lot of attention at national and regional level in the last few years. It is now 10 years since the first biosimilar was approved in the European Union, but do policies in the Member States take the differences between biological medicines and small-molecule generics into account? To map the policy landscape in Europe, European Biopharmaceutical Enterprises (EBE) has conducted a second round of its descriptive survey of pricing and reimbursement policies for off-patent biologicals.
    Read more |